爱尔兰爵士制药去纤苷的副作用有什么？

(Defibrotide) is a sodium salt of single-chain polydeoxyribonucleoside. In recent years, studies have confirmed that it is effective in the treatment of hepatic veno-occlusive disease (HVOD), with a remission rate of 42%, and has low toxicity and does not affect systemic coagulation activity. In vitro and in vivo experimental studies have shown that defibrotide can stimulate the release of TM, t-PA, prostaglandin, and prostaglandin E2, reduce thrombin generation, TF expression, PAI-1 release, and endothelial activation; it can significantly reduce LPS-induced TF expression in microvascular endothelial cells, and neutralize the LPS-induced increase in PAI-1 level expression and decrease in t-PA expression; thus reducing the procoagulant activity of endothelial cells and improving their fibrinolytic activity.

However, Irish Jazz Pharmaceuticals' Defibrinoside still has certain side effects, the most common of which include hypotension, diarrhea, vomiting, nausea, and nosebleeds.较严重的潜在副作用包括出血及过敏反应。 有出血并发症 、正在服用血液稀释药物或其他可能影 响血液凝结药物的人禁用去纤苷 。

The U.S. FDA approved Defitelio (defibrotidesodium, sodium defibrotide) on March 30, 2016, for the treatment of severe hepatic veno-occlusive disease in adults and children after hematopoietic stem cell transplantation (usually complicated by renal and lung function abnormalities). The FDA also granted it orphan drug status.去纤苷由 Jazz（爵士）药业公司(JazzPharmaceuticals)销售。 Sir Irish Pharmaceuticals is a public limited liability company established under the laws of Ireland in March 2005. It is primarily focused on the identification, development and commercialization of pharmaceutical products to meet significant medical needs. As a drug under the company, it has received widespread attention once it was launched.

Recommended hot articles: /newsDetail/87111.html